TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
LOS ANGELES, Sept. 15, 2024 /PRNewswire/ — TORL BioTherapeutics, LLC (“TORL Bio” or “the Company”), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced the presentation of additional results from the ongoing Phase 1 study of TORL-1-23, the Company’s Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) in patients with advanced cancer at the 2024 European Society of Medical Oncology Congress (ESMO 2024) in Barcelona, Spain.
TORL BioTherapeutics Announces Appointment of Howard A. “Skip” Burris III, MD, FACP, FASCO as Board Member
TORL BioTherapeutics, LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced the appointment of Howard A. “Skip” Burris III, MD, FACP, FASCO as Board Member.
TORL Biotherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
TORL BioTherapeutics, LLC (TORL), is a clinical-stage biotechnology company involved in discovery and development of new antibody-based immunotherapies designed to improve and extend the lives of patients with cancer worldwide. Today, the Company announced its closing of an oversubscribed $158 million Series B-2 financing. The financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management, Perceptive Advisors, and Avidity Partners as well as all existing biotechnology investors including Goldman Sachs Alternatives, UC Investments, Bristol Myers Squibb, Vertex Ventures HC, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, and Perceptive Xontogeny Venture Fund, brings the total raised to date to greater than $350 million. Proceeds from this Series B-2 financing will be used to continue the clinical development of TORL-1-23, the Company’s first-in-class ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024. This Phase 2 trial is designed to facilitate regulatory review and potential approvals for TORL-1-23 as a new therapy for patients with CLDN 6+, platinum-resistant ovarian cancer. Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors.
TORL Biotherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs
Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL’s Chairman and CEO. Mark brings more than 35 years of global biopharmaceutical experience, and will lead TORL as it advances its expanding clinical-stage antibody programs in oncology and builds additional programs through the high-value discovery pipeline established and led by TORL Scientific Founder Dennis Slamon, M.D., Ph.D.
TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
LOS ANGELES, June 1, 2023 /PRNewswire/ — TORL BioTherapeutics LLC (“TORL Bio” or “the Company”) announces the initial results from an ongoing phase I study of their claudin 6 (CLDN6) targeted antibody drug conjugate (ADC), TORL-1-23, in patients with advanced cancer on the American Society of Oncology (ASCO) website
TORL Biotherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing.